You are here:

montelukast (Singulair paediatric)

Advice

Following a full submission

montelukast chewable tablet and granules (Singulair Paediatric) is accepted for restricted use within NHS Scotland as an alternative treatment option to low-dose inhaled corticosteroids for patients, [children 2 to 14 years of age] with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.

It should be restricted to initiation by specialists in paediatric asthma care.

Drug Details

Drug Name: montelukast (Singulair paediatric)
SMC Drug ID: 383/07
Manufacturer: MSD
Indication: Asthma in Children aged 2 -14 years
BNF Category:
Sub Category: 3.3 Cromoglicate and related therapy and leukotriene receptor antagonists
Submission Type: Full submission
Status: Restricted
Date Advice Published: 9 July 2007

Back